Visiopharm

Company profile

About Visiopharm

Visiopharm is a leading provider of AI-driven precision pathology software serving both research and diagnostic markets. Founded in 2002, the company combines 20 years of pathology expertise with advanced artificial intelligence to deliver accurate and versatile tissue analysis solutions. In research, Visiopharm provides technology leadership through tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. Their flagship products include Discovery for tissue image analysis and Phenoplex for spatial biology, both featuring deep learning capabilities and customizable workflows. In diagnostics, Visiopharm leads in clinical applications with nine diagnostic algorithms cleared under IVDR for EU customers, providing diagnostic decision support that integrates seamlessly into existing laboratory workflows through PACS/IMS systems like Sectra IDS7 and Proscia Concentric AP. The company also offers Qualitopix for IHC staining consistency measurement and quality control. Visiopharm serves over 750 customer accounts across more than 40 countries, supporting applications in oncology, neurology, hepatology, nephrology, dermatology, and other therapeutic areas. Their software enables researchers and pathologists to build tailored analysis workflows for drug discovery, spatial biology, clinical research, and laboratory-developed tests (LDTs). The company is privately owned and operates internationally with headquarters in Denmark's Medicon Valley and legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, plus local representation in France and China.

Company description · Visiopharm official website